Qurient Co., Ltd. 115180

KRX · South Korea · Health Technology

KRW 24,650.00+2,650.00 (+12.05%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Company news

Yahoo FinanceJun 01, 2026

Qurient Announces First Patient Dosed in Phase 2 Trial of Novel CDK7 Inhibitor Mocaciclib (Q901) for the treatment of HR-Positive Breast Cancer

SEONGNAM, South Korea, June 01, 2026--Qurient announced the first patient dosed in a Phase 2 study of mocaciclib (Q901) for CDK4/6 inhibitor-resistant HR+ breast cancer.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.